title: Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors.
abstract: Opioid agonists (ethylketocyclazocine, etorphine, [D-Ala2,D-Leu5]enkephalin (DADLE), [D-Ala2, N-Me-Phe4-Gly-ol]enkephalin (DAGO), [D-Ser2,Leu5]enkephalin-Thr6 (DSLET) and morphine were found to inhibit the proliferation of human prostate cancer cell lines (LNCaP, DU145, and PC3), in a dose-dependent manner. The 50% inhibitory concentrations (IC50) were in the picomolar range. In many cases, this effect was antagonized by the general opioid antagonist, diprenorphine, indicating the existence of specific opioid binding sites. Saturation binding experiments with selective ligands and effectors showed no opioid sites on the LNCaP cell line, kappa1 and mu sites on the PC3 cell line, and kappa1, kappa3 and mu sites on the DU145 cell line. In other cases, the opioid effect was not antagonized by diprenorphine, indicating that the action of opioids might be mediated through other membrane receptors. Furthermore, casomorphin peptides, issued from bovine alpha- (alpha-casein-90-95 and alpha-casein-90-96) and beta-caseins (beta-casomorphin and beta-casomorphin-1-5), and human alphaS1-casein (alphas -casomorphin and alphaS1-casomorphin amide) inhibited cell proliferation of human prostate cell lines, also by a mechanism partly involving opioid receptors. As opioid neurons can be found in the prostate gland, and casomorphin peptides might reach the gland through the general circulation, the above findings indicate a putative role of opioids in prostate cancer cell growth.
authors.affiliation: Laboratory of Experimental Endocrinology, University of Crete, School of Medicine and University Hospital, Heraklion, Greece.
authors.forename: M
authors.initials: M
authors.lastname: Kampa
authors.forename: E
authors.initials: E
authors.lastname: Bakogeorgou
authors.forename: A
authors.initials: A
authors.lastname: Hatzoglou
authors.forename: A
authors.initials: A
authors.lastname: Damianaki
authors.forename: P M
authors.initials: PM
authors.lastname: Martin
authors.forename: E
authors.initials: E
authors.lastname: Castanas
mesh_terms: D001665:Binding Sites; D002364:Caseins / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004745:Enkephalins / Q000494:pharmacology; D016314:Ethylketocyclazocine / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D008297:Male; D009019:Morphinans / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D011957:Receptors, Opioid / Q000819:agonists*; D014407:Tumor Cells, Cultured
chemical_list: D002364:Caseins; D004745:Enkephalins; D008024:Ligands; D009019:Morphinans; D009292:Narcotic Antagonists; D009294:Narcotics; D011957:Receptors, Opioid; D016314:Ethylketocyclazocine